Tepotinib
Tepotinib is a once-daily targeted pill for lung cancers driven by a MET exon 14 skipping mutation, and the MET inhibitor NICE funds in England.
Overview
Tepotinib is an oral MET inhibitor for advanced non-small cell lung cancer with MET exon 14 skipping alterations, which can be detected in tumour tissue or in circulating tumour DNA. The VISION trial showed durable responses in about half of patients whether or not they had been treated before. Japan approved it first in 2020, the FDA in 2021 and the EU in 2022. NICE recommended it in 2022 within its licence with a commercial arrangement. Peripheral oedema is the main side effect.
A highly selective, once-daily MET kinase inhibitor that blocks signalling from MET receptors kept active by exon 14 skipping mutations. Connects to MET.
1.Tepotinib slips into a pocket on MET.
- Appraised for
- Advanced NSCLC with MET exon 14 skipping alterations
- Notes
- Published 18 May 2022, within the licence with a commercial arrangement; the only MET inhibitor routinely funded in England.
- NHS England
- Routinely funded for the appraised indication (or via managed access)
Sources: NICE TA789. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Metastatic NSCLC with MET exon 14 skipping alterations |
| EU | 2022 | Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy |
| JP | 2020 | Unresectable advanced or recurrent NSCLC with MET exon 14 skipping |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Tepotinib" OR ABSTRACT:"Tepotinib" OR TITLE:"Tepmetko" OR ABSTRACT:"Tepmetko" OR TITLE:"MSC2156119" OR ABSTRACT:"MSC2156119" OR TITLE:"EMD 1214063" OR ABSTRACT:"EMD 1214063") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tepotinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCrizotinib
Shares Capmatinib, MET, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentCeritinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentBrigatinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentDacomitinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentMobocertinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentTaletrectinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentEnsartinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentSunvozertinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.